- Home
- CHRS vs CHGG Comparison
CHRS vs CHGG Comparison
Compare CHRS & CHGG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CHGG
- Stock Information
- Founded
- CHRS 2010
- CHGG 2005
- Country
- CHRS United States
- CHGG United States
- Employees
- CHRS 235
- CHGG N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CHGG Other Consumer Services
- Sector
- CHRS Health Care
- CHGG Real Estate
- Exchange
- CHRS Nasdaq
- CHGG Nasdaq
- Market Cap
- CHRS 134.4M
- CHGG 154.4M
- IPO Year
- CHRS 2014
- CHGG 2013
- Fundamental
- Price
- CHRS $1.16
- CHGG $1.51
- Analyst Decision
- CHRS Strong Buy
- CHGG Hold
- Analyst Count
- CHRS 4
- CHGG 10
- Target Price
- CHRS $5.38
- CHGG $4.56
- AVG Volume (30 Days)
- CHRS 2.4M
- CHGG 2.6M
- Earning Date
- CHRS 03-12-2025
- CHGG 02-24-2025
- Dividend Yield
- CHRS N/A
- CHGG N/A
- EPS Growth
- CHRS N/A
- CHGG N/A
- EPS
- CHRS N/A
- CHGG N/A
- Revenue
- CHRS $304,340,000.00
- CHGG $662,077,000.00
- Revenue This Year
- CHRS $2.47
- CHGG N/A
- Revenue Next Year
- CHRS N/A
- CHGG N/A
- P/E Ratio
- CHRS N/A
- CHGG N/A
- Revenue Growth
- CHRS 44.19
- CHGG N/A
- 52 Week Low
- CHRS $0.66
- CHGG $1.34
- 52 Week High
- CHRS $2.87
- CHGG $9.75
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- CHGG 40.79
- Support Level
- CHRS $1.03
- CHGG $1.41
- Resistance Level
- CHRS $1.39
- CHGG $1.76
- Average True Range (ATR)
- CHRS 0.14
- CHGG 0.11
- MACD
- CHRS -0.03
- CHGG 0.01
- Stochastic Oscillator
- CHRS 14.04
- CHGG 10.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About CHGG Chegg Inc.
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.